POINT-Logo-Colour (blue).png
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
12 août 2022 08h30 HE | POINT Biopharma
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
11 août 2022 16h15 HE | Aprea Therapeutics
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
Onconova Logo BLUE.jpg
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
11 août 2022 16h05 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Cancer Support Commu
Cancer Support Community and Carevive Partner on Innovative Care Delivery Model
11 août 2022 13h00 HE | Cancer Support Community
WASHINGTON, D.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) and Carevive are partnering to provide an innovative nursing and social work team-based care delivery model to...
MNPR Triangle 2.JPG
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
11 août 2022 08h05 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Summit-logo-RGB.png
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
11 août 2022 08h00 HE | Summit Therapeutics Inc.
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
shattuck-logo-dark-h.png
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights
11 août 2022 07h00 HE | Shattuck Labs, Inc.
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3’2022 with initial combination data expected...
new_logo.png
Imaging Agents Market Trends 2022 | North America, Europe, & APAC Industry Forecasts 2028: Graphical Research
10 août 2022 08h00 HE | Graphical Research
Pune, India, Aug. 10, 2022 (GLOBE NEWSWIRE) -- The global imaging agents market size is estimated to increase exponentially during the forecast period, attributed to rising demand for innovative...
RevolutionLogo.png
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
09 août 2022 16h02 HE | Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...
Summit-logo-RGB.png
Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
09 août 2022 13h37 HE | Summit Therapeutics Inc.
Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully-subscribed...